Ultragenyx Pharmaceutical Inc. (RARE)
UnterbewertetFundamental
34
Kurs
$15.03
Marktkapitalisierung
$1.48B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$717M
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-586M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$-472M
Gesamtes Eigenkapital
$-80M
Gesamtverbindlichkeiten
$1.60B
Current Ratio
1.73
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$28.05
Aktueller Kurs
$15.03
Sicherheitsmarge
+46.4%
Innerer-Wert-Spanne
$26.65 - $29.46
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
718.8%
P/B-Verhältnis
-
P/FCF
-
Bruttomarge
-
ROIC
-45.7%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
-45.7%
WACC
4.5%
ROIC − WACC
-50.1 pp
Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.
Fundamentalanalyse-Kriterien
Bestanden (5)
- EPS shows upward trend
- Current Ratio
- Revenue Growth 5Y 19.9%
- Analyst Consensus 88% Buy
- Net Margin Trend -81.7% vs -87.3%
Nicht bestanden (11)
- Price CAGR -14.39%
- ROIC -45.7%
- Operating Margin -73.6%
- Positive Free Cash Flow
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Unknown)
- ROE -414.2%
- Earnings Surprise avg -12.9%
- Share Dilution 9.0%
- Piotroski F-Score 4/9
Nicht verfügbar (11)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director | 65 |
| Mr. Howard Horn | Executive VP of Corporate Strategy & CFO | 46 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs | 47 |
| Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer | 55 |
| Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP | 52 |
| Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer | 54 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP | 60 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 60 |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations | - |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences | 59 |
Prüfungsrisiko
5
Vorstandsrisiko
2
Vergütungsrisiko
8
Aktionärsrechterisiko
7
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-18
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-08-05
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-09-17
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for RARE, sourced from Markets Gazette.
- 3/12/2026POSITIVEUltragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder
Ultragenyx Pharmaceutical Inc. announced positive Phase 3 data for its gene therapy candidate, demonstrating a significant reduction in ammonia levels for patients with a rare metabolic disorder. While full clinical outcomes are anticipated in 2027, the early success in normalizing key biomarkers offers a promising outlook. This development could position Ultragenyx as a leader in treating ultra-rare genetic diseases, potentially leading to substantial market share and improved patient lives, which is a strong signal for investors.
via Markets Gazette